Insight

Oct 16, 2024, 15:08

The utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC

Drew Moghanaki shared a post on X:

“A new publication from Max Diehn‘s group re-demonstrates the utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC.

Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC

Authors: Soyeong Jun, Nikhil A. Shukla, Greg Durm, Angela B. Hui, Sha Cao, Apar Kishor Ganti, Salma K. Jabbour, Christian Kunder, Ash A. Alizadeh, Nasser H. Hanna, Maximilian Diehn.“

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).

Angela B. Hui Apar Kishor Ganti Ash A. Alizadeh cancer Christian Kunder CRT ctDNA Drew Moghanaki Greg Durm Maximilian Diehn Nasser H. Hanna Nikhil A. Shukla OncoDaily Oncology Salma K. Jabbour Sha Cao Soyeong Jun stage III NSCLC

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Speakers of the 2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents

Alcohol and Cancer Risk: The U.S. Surgeon General’s Advisory 2025

The agenda for the 2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents

Special Coverage